Wheeler Sydney, Mahmoudzadeh Raziyeh, Randolph Jessica
Virginia Commonwealth University School of Medicine.
Virginia Commonwealth University Department of Ophthalmology, Richmond, Virginia, USA.
Curr Opin Ophthalmol. 2024 Sep 1;35(5):359-364. doi: 10.1097/ICU.0000000000001064. Epub 2024 Jun 13.
This review highlights treatment options, both under investigation and currently available, for the treatment of dry age-related macular degeneration (AMD). An update on current clinical studies for dry AMD has been summarized.
Advanced dry AMD, characterized by geographic atrophy (GA), is a leading cause of blindness in the developed world, though prior to 2023 there was no approved treatment. There are now two approved treatments in the United States for GA. Additionally, there are several studies and trials to investigate therapeutic potential and effects of therapies for earlier intervention in dry AMD. Approaches to therapy include inhibiting the complement system, utilizing gene therapy, stem cell therapy, laser therapy, and surgical implants.
While there has been notable prior advancement in the treatment for neovascular or wet AMD, for the first time there are Food and Drug Administration (FDA) approved treatments for GA. Clinical studies have shown promise for additional methods for managing dry AMD both medically and surgically.
本综述重点介绍了正在研究和目前可用的治疗干性年龄相关性黄斑变性（AMD）的方法。总结了干性AMD当前临床研究的最新情况。
以地图样萎缩（GA）为特征的晚期干性AMD是发达国家失明的主要原因，不过在2023年之前尚无获批的治疗方法。目前美国有两种针对GA的获批治疗方法。此外，还有多项研究和试验来探究干性AMD早期干预疗法的治疗潜力和效果。治疗方法包括抑制补体系统、利用基因疗法、干细胞疗法、激光疗法和手术植入。
虽然之前在新生血管性或湿性AMD的治疗方面取得了显著进展，但美国食品药品监督管理局（FDA）首次批准了针对GA的治疗方法。临床研究表明，在医学和手术治疗干性AMD的其他方法方面具有前景。
